Literature DB >> 9371372

In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.

R C Mercier1, S R Penzak, M J Rybak.   

Abstract

We evaluated the in vitro activities of clinafloxacin, CL331,002, LY333328, quinupristin dalfopristin, and eperezolid (formerly known as U-100,592) against four strains of enterococci. All regimens tested resulted in the growth inhibition of each isolate. Against the three clinafloxacin-susceptible strains, clinafloxacin tested alone was the most active treatment, decreasing the bacterial inoculum by more than 3 log10 CFU/ml after 24 h in time-kill curve studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371372      PMCID: PMC164167     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  The Garrod Lecture. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options.

Authors:  R C Moellering
Journal:  J Antimicrob Chemother       Date:  1991-07       Impact factor: 5.790

2.  Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital.

Authors:  I Nachamkin; P Axelrod; G H Talbot; S H Fischer; C B Wennersten; R C Moellering; R R MacGregor
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

Review 3.  An overview of nosocomial infections, including the role of the microbiology laboratory.

Authors:  T G Emori; R P Gaynes
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

Review 4.  Genetics and mechanisms of glycopeptide resistance in enterococci.

Authors:  M Arthur; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

5.  Activity of clinafloxacin against multidrug-resistant Enterococcus faecium.

Authors:  S Burney; D Landman; J M Quale
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

6.  CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; K C Lamp; E M Bailey; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

7.  High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections.

Authors:  L M Bush; J Calmon; C L Cherney; M Wendeler; P Pitsakis; J Poupard; M E Levison; C C Johnson
Journal:  Ann Intern Med       Date:  1989-04-01       Impact factor: 25.391

8.  Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative.

Authors:  S R Norrby; M Jonsson
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

9.  Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots.

Authors:  S L Kang; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

10.  Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256.

Authors:  D M Shlaes; A Bouvet; C Devine; J H Shlaes; S al-Obeid; R Williamson
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

View more
  10 in total

1.  Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.

Authors:  S Brisse; A C Fluit; U Wagner; P Heisig; D Milatovic; J Verhoef; S Scheuring; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.

Authors:  S O Matsumura; L Louie; M Louie; A E Simor
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Vancomycin-Resistant Enterococcus: Infectious Endocarditis Treatment.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

4.  Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.

Authors:  T Schülin; C Thauvin-Eliopoulos; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.

Authors:  E A Coyle; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.

Authors:  D L Stevens; L G Smith; J B Bruss; M A McConnell-Martin; S E Duvall; W M Todd; B Hafkin
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.

Authors:  A Lefort; A Saleh-Mghir; L Garry; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.

Authors:  Adam Belley; Eve Neesham-Grenon; Francis F Arhin; Geoffrey A McKay; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

Review 10.  Oxazolidinones: a review.

Authors:  D I Diekema; R N Jones
Journal:  Drugs       Date:  2000-01       Impact factor: 11.431

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.